UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease

The New England journal of medicine, 2022-11, Vol.387 (20), p.1855-1864

2022

Volltextzugriff (PDF)

Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)

The American heart journal, 2022-09, Vol.251, p.61-69

2022

Volltextzugriff (PDF)

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

Journal of the American College of Cardiology, 2014-06, Vol.63 (23), p.2541-2548

2014

Volltextzugriff (PDF)

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

The Lancet (British edition), 2012-12, Vol.380 (9858), p.1995-2006

2012

Volltextzugriff (PDF)

Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure

Journal of the American College of Cardiology, 2016-03, Vol.67 (12), p.1444-1455

2016

Volltextzugriff (PDF)

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance: The GAUSS-2 Randomized, Placebo-Controlled Phase 3 Clinical Trial of Evolocumab

Journal of the American College of Cardiology, 2014-06, Vol.63 (23), p.2541-2548

2014

Volltextzugriff (PDF)

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

The New England journal of medicine, 2021-01, Vol.384 (2), p.105-116

2021

Volltextzugriff (PDF)

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

The New England journal of medicine, 2017-05, Vol.376 (18), p.1713-1722

2017

Volltextzugriff (PDF)

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial

European journal of preventive cardiology, 2021-07, Vol.28 (8), p.805-812

2021

Volltextzugriff (PDF)

Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study

Journal of the American College of Cardiology, 2016-03, Vol.67 (12), p.1444-1455

2016

Volltextzugriff (PDF)

ASSOCIATION OF BASELINE LIPOPROTEIN(A) AND PERCENTAGE OF LIPOPROTEIN(A) LOWERING WITH OLPASIRAN

Journal of the American College of Cardiology, 2023-03, Vol.81 (8), p.1130-1130

2023

Volltextzugriff (PDF)

The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering

Journal of the American College of Cardiology, 2024-08, Vol.84 (9), p.790-797

2024

Volltextzugriff (PDF)

The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results

Journal of the American College of Cardiology, 2024-08, Vol.84 (9), p.790

2024

Volltextzugriff (PDF)

Promotion of Central Cholinergic and Dopaminergic Neuron Differentiation by Brain-Derived Neurotrophic Factor but not Neurotrophin 3

Proceedings of the National Academy of Sciences - PNAS, 1991-02, Vol.88 (3), p.961-965

1991

Volltextzugriff (PDF)

Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia

Circulation (New York, N.Y.), 2008-01, Vol.117 (4), p.526-535

2008

Volltextzugriff (PDF)

Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study

Journal of clinical lipidology, 2019-11, Vol.13 (6), p.901-909.e3

2019

Volltextzugriff (PDF)

Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device

Scientific reports, 2024-01, Vol.14 (1), p.1754-1754, Article 1754

2024

Volltextzugriff (PDF)

Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction-DOSE Finding Study) Trial

The American heart journal, 2022-05

2022

Volltextzugriff (PDF)

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial

European journal of preventive cardiology, 2020-02, p.2047487320902750

2020

Volltextzugriff (PDF)

K‐252 Compounds: Modulators of Neurotrophin Signal Transduction

Journal of neurochemistry, 1992-12, Vol.59 (6), p.1987-1996

1992

Volltextzugriff (PDF)

Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy

Clinical cardiology (Mahwah, N.J.), 2012-07, Vol.35 (7), p.385-391

2012

Volltextzugriff (PDF)

The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure

European journal of heart failure, 2009-11, Vol.11 (11), p.1071-1077

2009

Volltextzugriff (PDF)

Heterodimeric Neurotrophins Induce Phosphorylation of Trk Receptors and Promote Neuronal Differentiation in PC12 Cells

The Journal of biological chemistry, 1995-09, Vol.270 (39), p.23104-23110

1995

Volltextzugriff (PDF)

Elevated mRNA expression of brain-derived neurotrophic factor in retinal ganglion cell layer after optic nerve injury

Investigative ophthalmology & visual science, 1997-08, Vol.38 (9), p.1840-1847

1997

Volltextzugriff (PDF)

Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II

The Journal of neuroscience, 1990-02, Vol.10 (2), p.558-570

1990

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(60)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(44)
Animals
(37)
Biological And Medical Sciences
(28)
Neurosciences
(27)
Neurosciences & Neurology
(27)
Humans
(26)
Rats
(26)
Female
(20)
Nerve Growth Factors - Pharmacology
(18)
Fundamental And Applied Biological Sciences. Psychology
(17)
Male
(15)
Neurons - Drug Effects
(12)
Aged
(11)
Brain-Derived Neurotrophic Factor
(11)
Medical Sciences
(11)
Vertebrates: Nervous System And Sense Organs
(11)
Cells, Cultured
(10)
Mice
(10)
Choline O-Acetyltransferase - Metabolism
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease

Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance: The GAUSS-2 Randomized, Placebo-Controlled Phase 3 Clinical Trial of Evolocumab

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial

Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study

ASSOCIATION OF BASELINE LIPOPROTEIN(A) AND PERCENTAGE OF LIPOPROTEIN(A) LOWERING WITH OLPASIRAN

The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering

The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results

Promotion of Central Cholinergic and Dopaminergic Neuron Differentiation by Brain-Derived Neurotrophic Factor but not Neurotrophin 3

Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia

Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study

Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device

Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction-DOSE Finding Study) Trial

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial

K‐252 Compounds: Modulators of Neurotrophin Signal Transduction

Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy

The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure

Heterodimeric Neurotrophins Induce Phosphorylation of Trk Receptors and Promote Neuronal Differentiation in PC12 Cells

Elevated mRNA expression of brain-derived neurotrophic factor in retinal ganglion cell layer after optic nerve injury

Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II

Suchergebnisse filtern